HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target

Benzinga · 10/11 10:33
HC Wainwright & Co. analyst Andrew Fein reiterates Sutro Biopharma (NASDAQ:STRO) with a Buy and maintains $12 price target.